头孢吡肟对体外敏感或敏感剂量依赖的碳青霉烯耐药肠杆菌目细菌的体内活性:对临床微生物实验室和临床医生的意义
本研究在小鼠大腿感染模型中评估头孢吡肟对产碳青霉烯酶(CP-CRE,n=21,blaKPC)和非产酶(非CP-CRE,n=19)碳青霉烯耐药肠杆菌目细菌的药动学/药效学。结果显示,体外敏感或敏感剂量依赖(SDD)的菌株均无法达到1 log细菌减少;CP-CRE较非CP-CRE疗效进一步减弱。结论提示应避免使用头孢吡肟治疗由体外敏感或SDD的CRE引起的严重感染。
要点
- 体外敏感或SDD的CRE菌株在小鼠模型中未达1 log杀菌。
- 产碳青霉烯酶CRE较非产酶CRE对头孢吡肟疗效更差。
- 相同MIC的菌株因耐药机制不同可有不同PK/PD表现。
核心结论
- 数据表明应避免使用头孢吡肟治疗由体外敏感或SDD的CRE引起的严重感染。
- 相同抗生素MIC的菌株因耐药机制不同可能具有不同的药动学/药效学特征。
研究设计与样本
- 研究采用小鼠大腿感染模型,纳入基因型特征明确的临床CRE分离株。
- CP-CRE(n=21;blaKPC)和非CP-CRE(n=19)菌株的头孢吡肟MIC分布为≤0.5至>256 mg/L。
- 小鼠接受模拟人类标准剂量(1 g q12h,0.5小时输注)或SDD剂量(2 g q8h,0.5小时输注)的头孢吡肟方案。
- 疗效评估为24小时细菌生长与0小时对照相比的变化,≥1 log细菌减少被认为具有临床疗效的转化价值。
主要发现
- 在体外对头孢吡肟SDD的CP-CRE和非CP-CRE菌株中,头孢吡肟均无法达到1 log细菌减少。
- 在敏感和SDD类别中,CP-CRE分离株较非CP-CRE分离株的头孢吡肟疗效进一步减弱。
临床怎么用
- 作者认为应避免使用头孢吡肟治疗由体外敏感或SDD的CRE引起的严重感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are a public health concern. Among these isolates, there are reports of isolates that test as cefepime susceptible or susceptible-dose dependent (SDD) in vitro despite presence of a carbapenemase. This study aimed to evaluate the pharmacokinetic/pharmacodynamic profile of cefepime against carbapenemase-producing (CP-CRE) and non-producing (non-CP-CRE) isolates with a range of cefepime MICs. METHODS: Reference broth microdilution and modified carbapenem inactivation method (mCIM) were performed on genotypically characterized clinical CRE isolates. Ultimately, CP-CRE (n = 21; blaKPC) and non-CP-CRE (n = 19) isolates with a distribution of cefepime MICs (≤0.5 to >256 mg/L) were utilized in the murine thigh infection model. Mice were treated with cefepime human-simulated regimens (HSRs) representative of a standard dose (1 g q12h 0.5 h infusion) or the SDD dose (2 g q8h 0.5 h infusion). Efficacy was assessed as the change in bacterial growth at 24 h compared with 0 h control, where ≥1 log bacterial reduction is considered translational value for clinical efficacy. RESULTS: Among both cohorts of CRE isolates, i.e. CP-CRE and non-CP-CRE, that tested as SDD to cefepime in vitro, 1 log bacterial reduction was not attainable with cefepime. Further blunting of cefepime efficacy was observed among CP-CRE isolates compared with non-CP-CRE across both susceptible and SDD categories. CONCLUSIONS: Data indicate to avoid cefepime for the treatment of serious infections caused by CRE isolates that test as cefepime susceptible or SDD. Data also provide evidence that isolates with the same antibiotic MIC may have different pharmacokinetic/pharmacodynamic profiles due to their antimicrobial resistance mechanism.
引用
- Fouad A, Gill CM, Simner PJ, et al. Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians. J Antimicrob Chemother. 2023. PMID: 37522258. doi:10.1093/jac/dkad229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。